Drug Profile
Research programme: natural killer T cell stimulants - NKT Therapeutics
Alternative Names: iNKT mAb; NKT 14m; NKTT 320Latest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator NKT-Therapeutics
- Class Antiasthmatics; Antineoplastics; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Natural killer T cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Asthma; Atopic dermatitis; Autoimmune disorders; Cancer
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for preclinical development in Asthma in USA (Parenteral)
- 28 Dec 2021 No recent reports of development identified for preclinical development in Atopic-dermatitis in USA (Parenteral)
- 28 Dec 2021 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (Parenteral)